Anavex Life Sciences Corp
North American company
Times are shown in GMT-5, values are delayed by at least 15 minutes. Past performance is not a reliable indicator of future results.
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2.Anavex Life Sciences Corp is a clinical stage bio-pharmaceutical company. The Company is engaged in the developments drug candidates to treat Alzheimer's disease, other central nervous system (CNS) diseases, and various types of cancer.
Latest AVXL News
Currently there are no news & analysis articles for this instrument. Visit our news hub for the latest investment news from ii and Alliance News